Boston Scientific aims to end Guidant brand
Firm seeks to distance itself from bad press after defibrillator woes
When Boston Scientific Corp. closed its $27 billion deal for Guidant Corp. last month, the Natick medical device maker planted its flag in the multibillion-dollar business of implantable defibrillators, the tiny and highly profitable machines that keep the heart from suddenly stopping. (Full article: 1118 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
